Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Renovacor, Inc. (RCOR : AMEX)
 
 • Company Description   
Renovacor Inc. is an early?stage biotechnology company developing adeno-associated virus based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants. Renovacor Inc., formerly known as Chardan Healthcare Acquisition 2 Corp., is based in NEW YORK.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.96 Daily Weekly Monthly
20 Day Moving Average: 17,133 shares
Shares Outstanding: 17.27 (millions)
Market Capitalization: $33.84 (millions)
Beta: 0.33
52 Week High: $10.74
52 Week Low: $1.95
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -49.74% -43.40%
12 Week -64.56% -61.04%
Year To Date -74.55% -68.42%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
201 Broadway Suite 310
-
Cambridge,MA 06836
USA
ph: 610-424-2650
fax: -
investors@renovacor.com http://www.renovacor.com
 
 • General Corporate Information   
Officers
Magdalene Cook - Chief Executive Officer; Chairman and President
Wendy DiCicco - Interim Chief Financial Officer
Gbola Amusa - Director
Edward J. Benz - Director
Gregory F. Covino - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 75989E106
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 17.27
Most Recent Split Date: (:1)
Beta: 0.33
Market Capitalization: $33.84 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.30 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.56
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -1,600.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -55.97
12/31/21 - -71.02
09/30/21 - -
ROA
03/31/22 - -25.32
12/31/21 - -11.82
09/30/21 - -18.79
Current Ratio
03/31/22 - 21.11
12/31/21 - 19.97
09/30/21 - 23.86
Quick Ratio
03/31/22 - 21.11
12/31/21 - 19.97
09/30/21 - 23.86
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 3.52
12/31/21 - 3.10
09/30/21 - 0.00
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©